Get the Stockscreener App
92.58
0.47%
-0.44
After Hours:
92.58
Guardant Health Inc stock is traded at $92.58, with a volume of 1.54M.
It is down -0.47% in the last 24 hours and down -5.88% over the past month.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
See More
Previous Close:
$93.02
Open:
$92.3
24h Volume:
1.54M
Relative Volume:
0.79
Market Cap:
$12.14B
Revenue:
$902.57M
Net Income/Loss:
$-398.79M
P/E Ratio:
-28.81
EPS:
-3.2131
Net Cash Flow:
$-274.52M
1W Performance:
-5.50%
1M Performance:
-5.88%
6M Performance:
+53.97%
1Y Performance:
+117.02%
1-Day Range:
$90.56
$96.52
1-Week Range:
$88.21
$96.98
52-Week Range:
$34.88
$120.74
Guardant Health Inc Stock (GH) Company Profile
Name
Guardant Health Inc
Sector
Industry
Phone
855-698-8887
Address
3100 HANOVER STREET, PALO ALTO
Compare GH vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
92.58 | 12.20B | 902.57M | -398.79M | -274.52M | -3.2131 |
|
TMO
Thermo Fisher Scientific Inc
|
518.84 | 192.62B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
202.00 | 144.77B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
618.92 | 51.65B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
118.11 | 34.09B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
315.59 | 31.30B | 3.17B | 642.63M | 516.49M | 10.77 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-20-26 | Reiterated | Canaccord Genuity | Buy |
| Feb-17-26 | Initiated | Robert W. Baird | Outperform |
| Jan-05-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Sep-25-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Sep-22-25 | Resumed | Wells Fargo | Overweight |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-28-24 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-26-23 | Upgrade | Citigroup | Neutral → Buy |
| May-05-23 | Initiated | UBS | Buy |
| Mar-09-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Nov-01-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-19-22 | Initiated | Craig Hallum | Buy |
| Oct-06-22 | Initiated | Stephens | Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Apr-28-22 | Resumed | BTIG Research | Buy |
| Feb-24-22 | Reiterated | Canaccord Genuity | Buy |
| Feb-24-22 | Reiterated | Citigroup | Buy |
| Feb-24-22 | Reiterated | Cowen | Outperform |
| Feb-24-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-24-22 | Reiterated | SVB Leerink | Outperform |
| Feb-24-22 | Reiterated | Stifel | Buy |
| Feb-24-22 | Reiterated | Wells Fargo | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-11-21 | Initiated | Stifel | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jun-12-20 | Initiated | BTIG Research | Buy |
| Feb-21-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Aug-07-19 | Reiterated | Canaccord Genuity | Buy |
| Apr-16-19 | Initiated | Canaccord Genuity | Buy |
| Apr-10-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-28-19 | Reiterated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | JP Morgan | Overweight |
| Oct-29-18 | Initiated | William Blair | Outperform |
View All
Guardant Health Inc Stock (GH) Latest News
BIAF vs. GH: Which Cancer Detection Stock Is the Better Buy Now? - Finviz
TEM's Diagnostics Arm Expanding Rapidly: What's Driving the Growth? - Yahoo Finance
Legato Capital Management LLC Has $677,000 Position in Guardant Health, Inc. $GH - MarketBeat
Amova Asset Management Americas Inc. Has $47.12 Million Position in Guardant Health, Inc. $GH - MarketBeat
ARK Investment Management LLC Sells 2,028,263 Shares of Guardant Health, Inc. $GH - MarketBeat
Guardant Health Targets Early Detection Growth With New Partner And Acquisition - simplywall.st
Shield mobile tour brings FDA-approved screening to 100 communities, Guardant Health announces - Traders Union
Guardant Health Launches Coast-to-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to Over 100 Communities Across America - Guardant Health
Blood test bus tour brings colon cancer screening to 100+ towns - Stock Titan
Segall Bryant & Hamill LLC Increases Stock Position in Guardant Health, Inc. $GH - MarketBeat
Actor and Cancer Advocate Patrick Dempsey Partners with Guardant Health to Raise Awareness about Colorectal Cancer Screening and Shield Blood Test, Sharing His Experience Getting Screened - Guardant Health
GH Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Intech Investment Management LLC Has $3.19 Million Stock Holdings in Guardant Health, Inc. $GH - MarketBeat
TD Asset Management Boosts Guardant Health Holdings - National Today
Guardant Health (GH) director acquires 154 shares via RSU vesting - Stock Titan
Guardant Health, Inc. (GH) Stock Analysis: A 41% Upside Potential With Strong Buy Ratings - DirectorsTalk Interviews
TD Asset Management Inc Boosts Holdings in Guardant Health, Inc. $GH - MarketBeat
Guardant Health, Inc. (GH) Strengthens Health Technology Portfolio with MetaSight Diagnostics Acquisition - Finviz
TD Cowen Health Care Conference - marketscreener.com
Guardant Health (GH) Is Down 8.9% After Issuing 2026 Guidance And New Equity Shelf Registration – Has The Bull Case Changed? - Yahoo Finance
11 Best Cancer Stocks to Invest In Now - Insider Monkey
Clover Health, Alignment Healthcare, Solventum, ANI Pharmaceuticals, and Guardant Health Shares Plummet, What You Need To Know - The Globe and Mail
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Erste Asset Management GmbH Buys 66,617 Shares of Guardant Health, Inc. $GH - MarketBeat
Colon cancer screening expands with simple blood test as cases rise among under-50s - WLUK
Guardant Health (GH) Gained from Better-Than-Expected Results - Insider Monkey
Guardant Health Stock Hits Day Low at $94.62 Amid Price Pressure - Markets Mojo
Guardant Health, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:GH) 2026-02-25 - Seeking Alpha
Guardant Health Stock Hits Day Low of $93.79 Amid Price Pressure - Markets Mojo
Single‑Reference Disclosures and the Motivation‑to‑Combine Requirement - The National Law Review
Liquidity Mapping Around (GH) Price Events - Stock Traders Daily
Piper Sandler Raises Guardant Health (GH) Price Target to $130 | - GuruFocus
Vanguard Group Inc. Reduces Position in Guardant Health, Inc. $GH - MarketBeat
Guardant Health acquires Israeli healthtech MetaSight for up to $150M - MSN
Guardant Health pushes for AI-driven oncology breakthroughs at Cancer 2035 - Traders Union
Guardant Health slides as investors digest Q4 results and a risk-off tape - Quiver Quantitative
Guardant Health, Inc. (GH) Stock Analysis: A 26.53% Upside Potential in the Precision Oncology Market - DirectorsTalk Interviews
Guardant Health acquires MetaSight amid positive 2026 financial outlook - Yahoo Finance
Guardant Health, PacBio, Align Technology, QuidelOrtho, and Omnicell Shares Are Falling, What You Need To Know - Finviz
Guardant buys MetaSight for $59M upfront to acquire blood test tech - MedTech Dive
Guardant Health Expands Cancer Testing Platform With MetaSight Deal And Shield Growth - Yahoo Finance
Skandinaviska Enskilda Banken AB publ Trims Holdings in Guardant Health, Inc. $GH - MarketBeat
Granite Investment Partners LLC Lowers Stake in Guardant Health, Inc. $GH - MarketBeat
Guardant Health Leads the Way in Blood-Based Single Cancer Screening - Morningstar
Can Guardant Health Inc. keep up with sector leadersMarket Risk Summary & Accurate Intraday Trade Tips - mfd.ru
State of New Jersey Common Pension Fund D Has $2.55 Million Holdings in Guardant Health, Inc. $GH - MarketBeat
Canaccord Genuity Group Forecasts Strong Price Appreciation for Guardant Health (NASDAQ:GH) Stock - Defense World
Guardant Health (NASDAQ:GH) Stock Price Expected to Rise, Leerink Partners Analyst Says - Defense World
Guardant Health Earnings Call Highlights Growth And Burn - TipRanks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Biogen (BIIB), Guardant Health (GH) and PTC Therapeutics (PTCT) - The Globe and Mail
Hillsdale Investment Management Inc. Acquires 19,800 Shares of Guardant Health, Inc. $GH - MarketBeat
Guardant Health Inc Stock (GH) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.14%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):